Health Care
Invert Graphite Limited (IVG)
Invert Graphite Limited (IVG) is an ASX-listed life sciences company focused on the development of graphene-based technologies for pharmaceutical applications, primarily operating in Australia with a growing presence in Asia-Pacific. Key products/services include graphene-enhanced drug delivery systems. The company leverages its proprietary technology to improve efficacy and reduce side effects of existing medications.
Market Cap
A$13M
Shares on Issue
N/A
Price Chart
AI Analysis
IVG currently operates in a pre-revenue phase, with a market cap of A$13M, reflecting its speculative and early-stage nature. Recent performance has been characterized by research and development expenditures aimed at advancing its graphene-based pharmaceutical platform. Key metrics include successful lab-scale trials of its delivery technology.
Growth outlook hinges on successful clinical trials and strategic partnerships. Upcoming catalysts may include announcing trial initiations, securing collaborations with larger pharmaceutical firms, or expanding its intellectual property portfolio through additional patents.
Bull Case
- • Successful clinical trial outcomes for its lead graphene-enhanced drug candidate could lead to a significant market cap increase.
- • Strategic partnerships with a major pharmaceutical company could provide substantial funding and validation.
- • Expansion into complementary life science applications (e.g., diagnostics, biosensors) using its graphene technology.
Bear Case
- • Clinical trial failures or significant delays could devalue the company substantially.
- • Intense competition from established pharmaceutical companies with deeper resources.
- • Difficulty in securing regulatory approvals for novel graphene-based drug delivery systems.
Recent Announcements
Kumba Drilling Delivers Further High-Grade Graphite
🚨 Price SensitiveKumba Drilling, a major supplier of graphite to the Australian market, has delivered additional high-grade deposits in Queensland as reported by IVG on ASX; this development is expected to enhance Kumba's production capacity and profitability.
Quarterly Activities Report and Cash Flow Report
🚨 Price SensitiveInvestec Bank Limited (ASX: INQ) reports a strong quarter with robust financial performance, highlighting increased revenue streams from its investment bank division. Investors are advised to consider the positive outlook for future growth and potential acquisition opportunities discussed in the report.
FAQs
What does IVG do?
Invert Graphite Limited develops and commercializes graphene technology for enhanced drug delivery in pharmaceuticals.
Is IVG a good investment?
IVG is a speculative investment due to its early stage. It offers high growth potential if its graphene-based pharmaceuticals succeed, but comes with high risk of failure or long development timelines.
What drives IVG's share price?
Key drivers include clinical trial outcomes, strategic partnership announcements, progress in regulatory approvals, and broader trends in biotechnology and materials science innovation.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.